loading page

DARATUMUMAB IN T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA: A CASE REPORT AND REVIEW OF THE LITERATURE
  • Sandra Ruhayel,
  • Santosh Valvi
Sandra Ruhayel
Perth Children's Hospital Department of Paediatric and Adolescent Oncology and Haematology
Author Profile
Santosh Valvi
Perth Children's Hospital Department of Paediatric and Adolescent Oncology and Haematology
Author Profile

Abstract

Relapsed/refractory paediatric T-ALL carries a dismal prognosis and newer therapy options are urgently needed. Daratumumab, an antibody to transmembrane protein CD38 expressed on T-cells, is currently under investigation as a targeted immunotherapy approach to T-ALL. A 2-year-old male with refractory T-ALL received off-label, monotherapy with daratumumab, resulting in a rapid partial response with minimal toxicity. This is the first documentation of daratumumab administered to a child with this indication, and supports its potential benefit in T-ALL.